skip to main content

Welcome to Evgen Pharma PLC

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation. Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology. We are also researching a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to turn this scientific promise into commercially successful products, addressing important clinical needs.

Evgen Pharma Image Strategy


Evgen Pharma has a clear strategy for driving shareholder value from its technology

Read more

Evgen Pharma Image History


Evgen Pharma has attracted a highly experienced commercial, scientific and advisory team

Read more

Evgen Pharma Image Organisation


Founded in 2007, Evgen Pharma has evolved quickly into a clinical stage company

Read more


Evgen Pharma is a publicly quoted company. It joined the AIM market of the London Stock Exchange in October 2015 and its shares trade under the ticker symbol EVG.

Find out more


Our clinical pipeline is derived from our proprietary Sulforadex® platform technology; a means of synthesising and concurrently stabilising sulforaphane-based compounds in a solid dose form. Lead product, SFX-01, has produced positive results in an open-label Phase II trial in patients with ER+ metastatic breast cancer that had previously become resistant to all prior hormone therapies

Metastatic breast cancer

Breast cancer is the biggest cause of cancer deaths in women worldwide. In around 75% of breast cancers, the hormone oestrogen plays a key part in tumour growth

Read more

Autism Spectrum Disorder (ASD)

ASD costs the UK at least £32bn per year in treatment, lost earnings, care and support; this is more than the economic burden of cancer, heart disease and stroke combined

Read more

Non-alcoholic steatohepatitis (“NASH”)

Non-alcoholic fatty liver disease is now regarded as the most common liver condition in the developed world and 10%-20% of these have NASH

Read more


The Sulforadex® stabilisation technology means that sulforaphane, and related analogues, can be delivered as a stable active in an oral pharmaceutical product.

Find out more